

Canadian Bronchiolitis Epinephrine Steroid Trial

Submission date 26/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 26/09/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 19/05/2025	Condition category Respiratory	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Amy Catherine Plint

Contact details
Children's Hospital of Eastern Ontario
401 Smyth Road
Ottawa
Canada
K1H 8L1
+1 8 737 7600 ext. 3237
plint@cheo.on.ca

Additional identifiers

Protocol serial number
MCT-67276

Study information

Scientific Title
A randomised controlled trial of nebulised epinephrine and oral dexamethasone in the treatment of outpatients with bronchiolitis

Acronym
CanBEST

Study objectives

We hypothesise that children presenting to the Emergency Department (ED) with bronchiolitis and who are treated with nebulised epinephrine and/or oral dexamethasone will have fewer hospitalisations and a shorter, less severe illness.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Children's Hospital of Easter Ontario Research Ethics Board gave approval in May 2004.

Study design

Randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Bronchiolitis

Interventions

1. Oral dexamethasone
2. Nebulised epinephrine

Trial details received: 12 Sept 2005

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Dexamethasone, epinephrine

Primary outcome(s)

Admission to hospital up to 7 days after enrolment

Key secondary outcome(s)

1. Time to discharge
2. Length and severity of symptoms
3. Change in RDAI
4. Economic costs
5. Change in oxygen saturation from baseline at times 60, 120, 180 and 240 minutes
6. Co-interventions
7. Return to be evaluated by health care provider for on-going symptoms related to bronchiolitis
8. Adverse events

Completion date

31/03/2008

Eligibility

Key inclusion criteria

1. Age 6 weeks to 12 months, either sex
2. Respiratory distress assessment instrument (RDAI) score of greater than 3 and less than 15
3. Diagnosis of bronchiolitis

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

6 weeks

Upper age limit

12 months

Sex

All

Total final enrolment

800

Key exclusion criteria

1. Asthma or any previous episode of wheezing treated with bronchodilators
2. Chronic cardiopulmonary disease
3. Presence of varicella or recent close contact
4. Severe respiratory distress
5. Recent treatment with oral or inhaled steroids
6. Insurmountable language barrier
7. Any child born at less than 37 weeks gestation who is less than 6 weeks corrected age

Date of first enrolment

01/04/2004

Date of final enrolment

31/03/2008

Locations

Countries of recruitment

Canada

Study participating centre
Children's Hospital of Eastern Ontario
Ottawa
Canada
K1H 8L1

Sponsor information

Organisation
Children's Hospital of Eastern Ontario (Canada)

ROR
<https://ror.org/05nsbhw27>

Funder(s)

Funder type
Research organisation

Funder Name
Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-67276)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	14/05/2009		Yes	No
Results article		16/05/2025	19/05/2025	Yes	No